Member Info for Jatw

Conference presentations are often a good idea....and will push a rising SP along.
I doubt investec clients will want to be force fed Clin until the market starts to rerate the Share price. What will be the catalyst? Some positive news about Proleukin sales. Iovance might have done that, but is delayed....when there is progress the SP may recover strongly, until then it will probably hover around 600-700.

I have added again today. Looking for a short term boost from a trade deal and lowEr default rate on the credit book as the end of the pandemic comes into view.
The Ibstock 340m and Baker Hughes 100m deals are signs that Just can compete with Rothesay and LGEN for moderate sized deals. This is a huge market of 2trn there is plenty of business to be done.
Looking for a rerating soon following a couple f years when the management has met its capital targets and turned it around. This will always trade at a discount to NAV, but the discount should not be 75%. A more reasonable 30-40% discount means a share price of 120-140p. That is what I am hoping for in 2-3 years time.

Before the mRNA vaccines published 95% effectiveness, the benchmark or target for efficacy was much lower reflecting traditional expectations.....what would have been a great success may now be a relative failure. Although it would still derive great benefits from use.
Will the bookings be withdrawn by govts? Or will the vaccine be rejected by the population?
Could be a bumpy ride if AZN vaccine falls some way short of the competition.
Btw I have just bought some more Azn taking the risk they will deliver strong results.

I am somewhat surprised there has not been an update on trading.

The 2020 results will be affected by lower AUM hitting fees and the costs of expanding the global footprint. However mgmt continued with its 3year capital generation target.
I would expect the dividend to be flat, if they wanted to cut it, there has been opportunity to do so, so this is an attractive dividend payer for atleast a couple of years.
Also expect some bolt on M&A.....perhaps a retail platform....II is preparing for IPO....so is “for sale”.

JJ if you refer to today’s RNS, this is a new fund that MNG is a cornerstone investor.....it is investing in music rights like Hipgnosis (not sure of the spelling)
Sadly not a major new investor.

However I am pleased to note the recovery in the SP, only down a tad over 10% since launch.....hopeful of getting back above 200 soon.

It can only be the US performance.....and shareholder behaviour.

A company can usually list on as many Markets as it wants to pay fees for.
For AIM investors it is reassuring to see that the recent deals with GenAtlantic and CPP have the shares admitted in London only - they cannot be traded in NY (not sure why this is the case it will be some regulatory or tax reason). It would seem a London listing will continue for some time.

Too early to judge....let’s see what the NASDAQ makes of the investment.
Likely to be a down day on profit taking.

CH did say in his Loncar session that there were other deals being pursued like GA....so here we have one. It seems 100m USD is the preferred deal size.

Terms are the same as the GenAtlantic second tranche (assuming the GA option does not get repriced). So it could be a replacement for or a doubling of that investment.....

it adds 6m atleast to the cash runway and to a smaller listing in HK/Shanghai when that happens.

A little disappointed with the timing of my trade yesterday...it is becoming a feature that I buy and then a new funding is announced...but these minor timing issues will be forgotten in a few years and this company has a much larger value.

We can anticipate a trading update in the next few weeks, whether this is in mid December or early January it should be strong and support further gains.....unwise to sell in the 90s as this can run up quickly with news.
If people get the habit of mouthwash this will be v profitable for a long time.

I have bought in at 590. Ready for the next move...hope it is up....

I have added about 10% to my holding so a modest overage down....let’s see how they go.

Felt the time was right to add again today.....I am sure HCM will head past 500 once More when approval is given to surufatinib which must be getting close.
Still need to spread the love around my other holdings...as getting a bit too HCM heavy.

Should be safely in the FT350 now.
Good they have done a couple of bulk annuity deals this HY.
Not sure we will get a trading update soon unless they are well ahead of expectations.

Prospect of rising interest rates (or atleast not lower rates) probably behind this rise....and of course the vaccines which may limit bond defaults.....

Still highly undervalued here......With large unrealised lossses it looks tempting to average down.

If they do, they will be the first listing in London, NY,HK and Shanghai.

One would hope for a large premium in any bid...
Perhaps A More likely scenario is that Pru Asia corp starts to break itself up......eg sell Japan and Korea where it ceased taking new insurance business a few years ago.....sell down its India holdings......

The projected capital and dividend returns from 21 onwards return approx 45% of today’s price....
If the company delivers on this, it will be rated more highly too....but even if the SP remains flat there are not many places to get that return.
Regular accumulation s best

It has been almost a year since the NDA was accepted.....and it was hoped that with some manufacturing elements previously covered by frquintinib that it would be quicker this time.

The approval must be coming soon....let’s hope it is not rejected.

Looks like the number of drug candidates could be back to 8 (plus the 4 pre clinical assets) Theliatinib has been (accidentally ?) missed off the list. It and epitinib don’t get any airtime, so I think they are likely to not progress much further.....it would be good for the company to be seen to be ruthless with failing experiments to pull them explicitly...or find a buyer to recoup some of the development costs.

At last some positive news....expanding this particular drug's indications is very welcome.
I would rather they do this Themselves than rely on others to revitalise a drug.

SP now back to results day....NEDs up 10% so far.
Can they produce more good news soon?